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Abstract
Doping with endocrine drugs is quite prevalent in amateur and professional athletes. The World Anti-Doping
Agency (WADA) has a list of banned drugs for athletes who compete and a strategy to detect such drugs. Some
are relatively easy, anabolic steroids and erythropoietin, and others more difficult, human growth hormone (rhGH)
and insulin like growth factor I (IGF-I). The use of such compounds is likely less in adolescent athletes, but the
detection that much more difficult given that the baseline secretion of the endogenous hormone is shifting during
pubertal development with the greatest rise in testosterone in boys occuring about the time of peak height velo-
city and maximal secretion of hGH and IGF-I.
This review notes the rationale, physiology, performance enhancement, adverse events and the detection of dop-
ing with insulin, rhGH, rhIGF-I, erythropoietin, and anabolic-androgenic steroids.
Introduction
Can one grow more rapidly during childhood and early
adolescence to a taller than genetically programmed
adult height or to a more robust body composition
given anabolic-androgenic steroids (AAS), human
growth hormone (rhGH), insulin-like growth factor
(rhIGF-I), insulin or erythropoietin? Does such growth
permit an adolescent to increase his/her performance
goals– whether faster (citius) in many events, higher
(altius) in jumping events and stronger (fortius)? Why
would one consider that possible? The more successful
late childhood and early adolescent age athletes are
often more physically mature than their age-peers [1].
Early adolescent development seemingly permits them
to use the strength and power in sport and performance
that their average (or even slowly) developing age-peers
have not yet attained. The exceptions might be those
athletes in the more aesthetic sports in which flexibility
and a lower center of gravity are more important than
size and strength. These are virtually exclusively in
females [1].
Most boys’ sports require high levels of strength and
power; however, at elite levels of competition technique
is a strong measure of success; for the athlete must pro-
duce, control and efficiently use the energy in a fashion
that maximizes athletic performance; for example,
explosive power in some jumping sports or overall
technical skill in the pole vault. Earlier developing chil-
dren are taller and stronger than their age-peers. That
may confer an advantage at younger ages; however,
sport-specific skills are important. It is because of these
that some of the “later blooming” adolescents catch-up
in performance with their earlier developing peers and
likely overtake them; for they have had the discipline to
attain the requisite skills and are perhaps at lesser risk
to “burn-out” and cease participation in that sport.
Background
The rationale for taking ergogenic “effectors”,s u c ha s
rhGH, rhIGF-I, anabolic steroids, insulin or erythropoie-
tin, is that by becoming bigger and stronger the athlete
will perform better. Some boys who are not athletes
take anabolic steroids and perhaps other ergogenic aides
to “look better”. However, there are no definitive data
for rhGH or insulin in young adults and none at all for
any of these five agents in adolescents who are not defi-
cient in them. In any experimental setting the study
design is such that one studies the effects of a single
agent with all other things being equal. For a drug one
decides on a dose, or range of doses and the subjects
are allocated randomly to receive or not receive a parti-
cular dose. The subjects should be selected from a com-
mon pool and all should have identical “requirements”,
for example, in studies of athletes, prescribed diet and
exercise regimens. It is apparent that many athletes take
a “cocktail” of drugs making it virtually impossible to
denote any single agent as causing a specific outcome.
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in adolescent high school athletes (4-12%), but not spe-
cifically in high level athletes. For the others there sim-
ply are no epidemiological data or data for doses,
duration, pharmacokinetics or pharmacodynamics. It is
quite unlikely that an ethical trial could be done in ado-
lescents. It should also be noted that just as in adults, it
is likely that adolescents combine dietary supplements
with one or more illegal agents.
Doping with Performance-Enhancing Endocrine
Drugs
Definition of Doping
The International Olympic Committee’s (IOC) definition
of doping is the “use of an expedient (substance or
method) which is potentially harmful to athletes’ health
and/or capable of enhancing their performance, or the
presence in the athletes’ body of a prohibited substance
or evidence of the use thereof or evidence of the use of a
prohibited method”. There is no mention of intent or of
how the substance entered the body. If the substance is
in the athlete’s body, then (s)he is responsible. That is
the basis of sanctions for testing positive for a prohib-
ited substance. Sir Arthur Porritt, first chairman of the
IOC Medical Commission, noted: “To define doping is, if
not impossible, at best extremely difficult, and yet every-
one who takes part in competitive sport or who adminis-
ters it knows exactly what it means. The definition lies
not in words but in integrity of character”.
Such agents are also known as “performance enhan-
cing substances” (PES) or “performance enhancing
drugs” (PED). The American Academy of Pediatrics
defines these agents as: “...any substance when taken in
non-pharmacological doses specifically for the purposes
of improving sport performance. A substance should be
considered performance enhancing if it benefits sports
performance by increasing strength, power, speed or
endurance (ergogenic) or by altering body weight or body
composition [2].
The agents that will be discussed are all hormones,
rhGH, rhIGF-I, insulin, anabolic steroids and
erythropoietin.
Insulin
Rationale
The primary source of carbohydrate during exercise
derives from muscle glycogen stores. The greater the
amount of glycogen stored, the longer one should be
able to exercise. Since insulin is a potent agent for the
uptake of glucose and the subsequent glycogen storage
in muscle, then the use of insulin ought to permit
longer exercise time. In addition, insulin leads to the
accumulation of amino acids in muscle and theoretically
additional substrate for protein synthesis. Insulin may
very well add to the anabolic properties of anabolic ster-
oids and/or rhGH or rhIGF-I. The most likely scenario
for a strength athlete would be to ingest a high carbohy-
drate diet, especially around the time of injecting rapidly
acting insulin or its analogues.
Physiology
Insulin stimulates the uptake of glucose into muscle and
fat by making available an increased number of glucose
transporters (Glut-4) at the cell membrane thus increas-
ing the flux of glucose to the interior of the cell. How-
ever, its main effect is inhibitory to lipolysis, glycolysis,
gluconeogenesis, ketogenesis and proteolysis [3,4].
Performance enhancement
The theoretical efficacy to improve performance–muscle
glycogen storage and the inhibition of proteolysis have
not been shown in experimental protocols. That does
not deter athletes from injecting insulin and its analo-
gues, likely because insulin is but one of a “cocktail” or
drugs along with training to enhance anabolic activity.
In addition one must consider more rapid recovery
from training and competition, but again there are no
data to show this effect.
Adverse events
The main adverse event is the most obvious, that of
hypoglycemia. Most athletes who abuse insulin are likely
adept at balancing the ingestion of carbohydrate when
injecting rapidly-acting insulin analogues. Much of the
use of insulin, which is readily available, is likely covert,
kept even from friends and family. It is unlikely that one
would tumble to the diagnosis of hypoglycemia in young
healthy, non-diabetic individuals when they present to
medical evaluation with confusion or coma. That can be
a fatal mistake.
Detection
There are no foolproof mechanisms for detecting insu-
lin, unless one uses an analogue and that or one of its
metabolites can be detected [5]. One would think that
anti-insulin antibody detection techniques would be
definitive, but there is a low frequency of circulating
anti-insulin antibodies in some normal (non-diabetic)
individuals.
Human Growth Hormone
Rationale
The rationale for adolescent athletes taking rhGH, is
that it should synergize with the physiologic (or doping)
increases in testosterone to grow faster and to add addi-
tional lean body mass [6]. It is understood that by
becoming bigger and stronger the athlete will perform
at a higher level. hGH is lipolytic in addition to being
anabolic and thus may be considered for those in “phy-
sique” related sports such as body-building. In multiple
surveys of adolescents who take anabolic agents, it is to
“look good” a so f t e na si ti st oa u g m e n ta t h l e t i c
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mance is much more than just strength or endurance;
for the athlete must produce, control and efficiently use
t h ee n e r g yi naf a s h i o nt h a tm a x i m i z e ss p o r t
performance.
Physiology
The most notable effect in children and adolescents is
linear growth. Growth hormone-deficient children and
adolescents are likely to be 20 to 30 cm shorter than
mid-parental target height if left untreated. Physiological
stimuli to hGH release include: deep sleep, some amino
acids and exercise. hGH is secreted in a pulsatile fashion
every hour or two and has significant peaks approxi-
mately 90 min after the onset of deep sleep and within
minutes of completing a bout of exercise. The main
(iso)form of hGH is a 191 amino acid, 22 kD peptide
with a significant amount of a 20 kD splice variant
form. There are a multitude of post-translationally mod-
ified forms including those affected by metabolism and
sulfation and phosphorylation. Several of the forms, pre-
dominantly the 22 kD and 20 kD forms interact with
the hGH receptor, a dimeric member of the cytokine
family of receptors at the cell surface to lead to the cel-
lular actions of hGH. One of the main ones is to stimu-
late the hepatic synthesis of IGF-I (endocrine), but also
to stimulate the paracrine and autocrine synthesis of
IGF-I in various tissues, such as bone and muscle [10].
In addition, it is lipolytic and can significantly alter
body composition by directing muscle protein synthesis
relative to fat. In fact, it is this action that has led to its
use in animal husbandry with the “partitioning” of feed
and “feed-efficiency” as the major outcomes [10].
Performance enhancement
D e s p i t et h ep a u c i t yo fd a t af o rp e r f o r m a n c ee n h a n c e -
ment, the “word on the street” is that this agent is quite
actively being abused by athletes. It is unlikely that the
athlete uses rhGH in isolation, thus making it quite dif-
ficult to define its exact role in athletic performance.
There is however one very well controlled study that
shows an effect on strength in a group of well defined
abstinent steroid abusers (subject to strict drugs of
abuse testing) [11]. There are no studies in child and
adolescent athletes, but it may be that faster growth,
weight gain and the salutary effects on body composi-
tion during adolescence could confer advantage to age-
group athletes, for it has been shown at the elite level
that the taller, heavier early adolescent athlete is repre-
sented out of proportion to his/her age-peers [1].
Adolescents reach “near-adult” height later in the teen
years with girls reaching this stature several years before
boys; however, the adult body composition (muscle,
bone and fat) and the regional distribution of body fat
are not attained until early-to-middle third decade. If
rhGH is effective to help one obtain these milestones
early, perhaps there is some advantage; however this is
quite theoretical [6].
Adverse events
There are many data for the short-term (years to more
than a decade) in children with a number of conditions
of childhood: GH deficiency, several genetic condition as
well as “short-normal” children. Two major data bases,
the Kabi International Growth Study (KIGS), now mana-
g e db yP f i z e r ,I n ca n dt h eN a t i o n a lC o o p e r a t i v eG r o w t h
Study produced and managed by Genentech, Inc show
quite low incidences of scoliosis, slipped capital femoral
epiphysis and rare instances of idiopathic intracranial
hypertension, the one of greatest concern. Adults have
noted more muscle and joint complaints than children.
There is the long-term (theoretical) issue of neoplasia.
Detection
The World Anti-Doping Agency (WADA) has placed
rhGH on its banned list and blood tests are available for
its detection. These have in their present iteration a
relatively small “window” for detection of doping. There
are two major methods for detection, the isoform
method [12] and the “markers” method [13], which have
been well-described and the details are beyond the pur-
pose of this review.
Insulin-like growth factor I
Rationale
The rationale for using rhIGF-I as an ergogenic aide dif-
fers little from that of rhGH. This compound has only
recently become more available and its use in athletes
will only increase. The potential benefits include
increased muscle protein synthesis and the sparing of
glycogenolysis with glycogen synthesis and increased
fatty acid availability
Physiology
IGF-I is the main effector for the action of hGH–see
above. Whereas hGH is insulin antagonistic several
hours after ingesting a meal, the main effect of hIGF-I is
to reduce glucose levels (insulin-like) and it is this effect
that has been noted clinically (see below). It is strongly
anabolic in muscle, but has a very much diminished
effect in comparison to hGH on lipids. In fact, children
with virtually no IGF-I (growth hormone receptor defi-
ciency, Laron-type) gain a disproportionate amount of
fat when treated for many years with rhIGF-I [14].
Performance enhancement
This is unknown at present. There just haven’t been stu-
dies in adults or children. rhIGF-I has been used as a
growth promoting agent in children with both primary
IGF-I deficiency and in a few genetic condition which
are associated with short stature. It is quite early for the
“efficacy” results, but growth rates have increased and it
is the only presently available drug for those with com-
plete growth hormone insensitivity.
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The major adverse event in children with growth hor-
mone insensitivity has been hypoglycemia; however,
most of the instances can be overcome with food inges-
tion around the time of the administration. Some
unique side effects include jaw pain, headache, fluid
retention and myalgia. As with rhGH there has been an
incidence of idiopathic intracranial hypertension. Similar
to the findings with rhGH stopping the drug for several
days and perhaps restarting at one-half dose seems pru-
dent in those who have experienced this adverse event.
In the longer term there is the theoretical aspect of
tumorigenesis, although no data exist, other than asso-
ciative ones for patients with certain cancers (for exam-
ple, breast, prostate, and colon) have had higher IGF-I
levels in the years before their cancers became detected
[15].
Detection
There is no specific test for rhIGF-I to detect doping.
The most likely approach will be to use the “markers”
method, described above for growth hormone [16].
Erythropoietin (EPO)
Rationale
Erythropoietin leads to the production of red blood
cells. Since these carry oxygen to active muscles, one
would consider enhanced endurance performance
because of the additional flux of oxygen.
Physiology
EPO is a circulating glycosylated protein hormone that
is the principal regulator of erythropoiesis. It is pro-
duced primarily by the kidney inversely related to the
concentration of O2 in the blood. Following administra-
tion, there is a direct relationship between haemoglobin
levels and increased performance following administra-
tion of rHuEPO in rats and humans [17]. Methods used
in doping include hypoxia and hypoxia-mimetics. One
such method is to train at altitude; however, one cannot
necessarily train as hard as at lower altitude because of
hypoxic-mediated fatigue. Variations on this theme
include living at altitude and training at sea level or
sleeping in a tent or chamber with diminished oxygen
tension (at lower altitude) and training at the same ele-
vation. These methods are not considered doping.
Performance enhancement
rHuEPO and its follow-on biological relatives can pro-
vide an effective mechanism to stimulate erythropoiesis
as noted above; however, the baseline hematocrit
increases and may rise even more to dangerous levels,
likely due to dehydration, in athletes during and after
training and competition. The rheology of blood
changes exponentially as the hematocrit rises above 55%
and accelerates even more rapidly as it rise above 60%.
Adverse events
Deaths in competitive cyclists have been directly linked
to changes in the flow properties of blood, as the hema-
tocrit rises. There are no studies of rHuEPO, or its
related proteins in child or adolescent athletes, but theo-
retically the responses should be no different from older
adolescents or young adults. The major issues are those
that relate to increased hematocrit- sluggish blood flow
in the small vessels of critical organs and pulmonary
emboli.
Detection
Detection of EPO and some of the follow-on drugs is
performed on urine sample using gel electrophoresis.
Each of the individual compounds (drugs) has a “signa-
ture” of glycosylation sites making the detection quite
precise [18].
Anabolic steroids
Rationale
Anabolic steroids regulate the building blocks for the
adolescent growth spurt and body composition. Even the
body uses the combination of testosterone, hGH and
IGF-I to subserve the adolescent growth spurt and the
“partitioning” (see above) of food energy into the various
compartments of body composition. As noted previously
the early attainment of pubertal development confers
some advantage on adolescent athletes compared to their
“on-time” peers, although this is likely less important
later in puberty given that sport-specific skills become
more important as the majority of athletes will have
entered and progressed through pubertal development.
Physiology
An anabolic steroid is a sex hormone that promotes the
development and maintenance of the male sex charac-
teristics. Testosterone is the principal secreted androgen
in men. Androgens have both masculinizing (develop-
ment of male secondary sex characteristics, including
hair growth) and anabolic effects (increase in skeletal
muscle mass and strength). For decades, pharmaceutical
companies have attempted to develop androgens that
have preferential anabolic activity and reduced or no
androgenic activity; these compounds have been referred
to as anabolic steroids.
There is feedback control of androgen synthesis and
secretion involving the hypothalamus (GnRH) and the
pituitary. During adolescence there are remarkable
alterations in both secretion and feedback sensitivity
that underpin male pubertal development. Testosterone
is strongly bound to sex-hormone binding globulin
(SHBG), loosely bound to albumin, and a small propor-
tion circulates as the free hormone. The biological activ-
ity is thought to reside in the free and loosely bound
(albumin-bound) fractions [19].
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[20] and an increase in the number of myonuclei and
satellite cells [21]. This metabolic action follows from
the binding of testosterone to the androgen receptor. Its
ability to transduce the binding of testosterone in the
cytoplasm of the cell to its anabolic action (altering
gene function in the nucleus) is inversely proportional
to the number of CAG repeats in the first exon of the
androgen receptor, a member of the nuclear transcrip-
tion factor family of receptors and located in virtually all
tissues [19].
Performance enhancement
There are many reports of muscle hypertrophy and
increases in strength in athletes who take anabolic ster-
oids. Virtually none are controlled trials of just testoster-
one or one of other anabolically-active steroids, for
many ingest and inject multiple potentially active drugs.
This subject has recently been exhaustively reviewed
[19].
The difficulty in adolescents is that increased secretion
of testosterone (and growth hormone) is a natural part
of human pubertal development. Thus it would be very
difficult to ascribe any individual changes noted in
strength and body composition to any pharmacological
agent at this time. The ethics of human experimentation
in adolescents precludes any serious objective study
using anabolic steroids
3.5.4 Adverse events
Adverse events in adolescents include those noted in the
adult–acne, shutting down of the hypothalamic-pitui-
tary-gonadal axis, unfavorable lipid profiles, hepatic dys-
function, psychological disturbances (so-called ‘roid’
rage) and other less common effects (reviewed exten-
sively in [19]). However, in addition, since testosterone
is a precursor to estrogens, there will be an acceleration
of epiphyseal maturation of the long bones and shorter
than predicted adult stature. In girls and women hirsut-
ism and disordered ovarian and menstrual cycles can
occur with quite small doses of anabolic steroids.
Detection
Much has been written in this area and I shall not
review it here. Methods using liquid chromatography
and mass spectrometry are the standard and “libraries”
of multiple compounds and their fragmentation pro-
ducts help to define the precise steroid taken. As noted
several years ago for tetrahydrogestinone, once the pure
compound is available a test can be validated very
quickly [22].
Conclusion
It is likely that drugs of abuse in adult athletes are also
used in adolescent athletes. The data for the later are
mainly theoretical because proper studies cannot be
ethically performed and it is unlikely that any of the
agents are taken in isolation.
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